Acthar凝胶治疗肌炎患者的随访结果
本研究对前瞻性开放标签RCI试验中难治性特发性炎症性肌病(IIM)患者进行6个月随访,每2个月评估核心指标。8例中4例在平均4.1个月后复发,其中3例需增加泼尼松;4例稳定者维持改善标准但无进一步改善。
要点
- 难治性IIM患者停用RCI后6个月内约半数复发,平均复发时间4.1个月。
- 复发者多需增加泼尼松;重启RCI者3个月改善甚微。
- 持续稳定者在6个月随访中维持改善标准但无额外疗效提升。
核心结论
- RCI试验后随访中,8例难治性IIM患者有4例在平均4.1个月时复发,4例稳定者维持改善但无进一步改善。
研究设计与样本
- 前瞻性开放标签RCI试验的事后随访研究,纳入难治性IIM患者,试验后随访6个月、每2个月评估一次。
主要发现
- 8例随访患者中4例在平均4.1个月后复发,其中3例需增加泼尼松。
- 1例在5.5个月重启RCI,3个月后改善甚微。
- 4例稳定患者持续满足改善定义至6个月随访,但主要和次要疗效结局均无进一步改善。
临床怎么用
- 难治性IIM患者经标准剂量和疗程RCI治疗后需密切随访,警惕停用后平均4.1个月左右的复发。
局限性
- 样本量小(8例随访),为开放标签试验的随访研究,非随机对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Idiopathic inflammatory myopathies (IIM) are a group of autoimmune diseases characterized by proximal muscle weakness. H. P. Acthar gel [repository corticotropin injection (RCI)] is a formulation of adrenocorticotropic hormone and has been approved by Food and Drug Administration for use in IIM; however, literature is limited. In this study, we report longitudinal follow-up of myositis patients treated with RCI. METHODS: Patients with refractory IIM who were enrolled in the prospective, open-label RCI trial were included in this study. The post-trial follow-up period was 6 months with assessments every 2 months, which included myositis core set measures including extra-muscular global, muscle and patient global disease activities, HAQ, and manual muscle testing. RESULTS: Two patients were lost to follow-up after finalization of the trial, and the remaining eight patients were enrolled in the follow-up study. One patient remained on RCI after the trial. In the follow-up period, four of eight patients had flare at on average 4.1 months after the RCI trial. Among the patients who flared, three required an increase in prednisone. One patient was restarted on RCI at 5.5 months, but had minimal improvement after 3 months. Four patients who remained stable continued to satisfy criteria for the definition of improvement through the 6-month follow-up. However, none showed any further improvement in the primary or secondary efficacy outcomes after the initial RCI trial. CONCLUSION: To our knowledge, this is the first study reporting the follow-up results of patients treated with standard dose and duration of Acthar. We believe that our study will provide the basis for the development of future randomized RCI trials in IIM.
引用
- Saygin D, Oddis CV, Marder G, et al. Follow-up results of myositis patients treated with H. P. Acthar gel. Rheumatology (Oxford). 2020. PMID: 32160301. doi:10.1093/rheumatology/keaa076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。